Skip to main content

Table 2 Comparison of the clinical characteristics and dasatinib pharmacokinetics in patients with and without a T315I mutation

From: Pharmacokinetics of dasatinib for Philadelphia-positive acute lymphocytic leukemia with acquired T315I mutation

 

T315I (n = 4)

Without T315I (n = 7)

P-Value

median (quartile 1- quartile 3)

median (quartile 1- quartile 3)

Sex Female

2 (50.0)

3 (42.9)

0.6515

Age (year)

67 (64–72)

56 (38.5 - 71)

0.4121

Bodily weight (kg)

50.3 (48.3 - 60.1)

49.0 (44.2 - 52.8)

0.7879

Body surface area (m2)

1.49 (1.46 - 1.57)

1.45 (1.39 - 1.57)

0.6485

White blood cell (*103/mm3)

2.4 (2.4 - 2.5)

3.7 (2.15 - 5.85)

0.3833

Red blood cell (*104 mm3)

248 (241–282)

291 (238–316)

0.8333

Platelet (*104 /mm3)

70 (50.5 - 77.5)

135 (117–167)

0.0167

Aspartate transaminase (IU/L)

32.5 (19.5 - 50)

33 (15.5 - 34)

0.5273

Alanine transaminase (IU/L)

23 (21–79)

23 (14–73.5)

0.7879

Serum albumin (g/dL)

4.3 (4.0 - 4.5)

3.9 (3.3 - 4.2)

0.2303

Total bilirubin (mg/dL)

0.4 (0.4 - 0.5)

0.4 (0.4 - 0.9)

0.9273

Serum creatinine (mg/dL)

0.6 (0.5 - 0.8)

0.6 (0.5 - 0.9)

0.7879

Single dose (mg)

100 (75–100)

100 (100–100)

0.7879

C0h (ng/mL)

0.2 (0.1 - 0.4)

0.0 (0.0 - 0.0)

0.1091

C1h (ng/mL)

13.2 (3.3 - 23.8)

49.0 (23.6 - 66.7)

0.0727

C2h (ng/mL)

22.3 (5.8 - 43.8)

111.6 (65.1 - 122.8)

0.0242

C4h (ng/mL)

34.6 (10.6 - 76.3)

69.7 (66.9 - 95.3)

0.1636

Cmax (ng/mL)

43.8 (19.1 - 77.0)

112.4 (95.3 - 122.8)

0.0242

AUC0-4h (ng·h/mL)

108.3 (49.2 - 139.2)

268.3 (220.0 - 307.3)

0.0061

  1. Data presented as numbers (%) of patients;
  2. Cnh, plasma concentration at n hour after dasatinib administration;
  3. Cmax, maximum plasma concentration less than 4 hours after dasatinib administration;
  4. AUC0-4h, area under the plasma concentration-time curve from 0 to 4 hours.